Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads

F. Raffi, V. Reliquet, D. Podzamczer, Richard B Pollard

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Purpose: The objective of this analysis was to assess the efficacy of nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing, protease inhibitor (PI)-sparing, three-drug highly active antiretroviral therapy (HAART) in HIV-1-infected, treatment-naive patients with high and low baseline viral loads. Method: A composite analysis was performed of clinical studies including the NNRTI nevirapine that were presented at international conferences between 1998 and October 2000. In all of the studies, nevirapine was administered in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). For a study to be included in the analysis, more than 25% of participants must have had baseline viral loads > 100,000 copies/mL, and more than 25% of participants must have had viral loads < 100,000 copies/mL. Results: After 6 months, 139 of 156 (89%) and 82 of 99 (83%) patients in the low and high baseline viral load groups, respectively, had on-treatment viral loads <200 to 500 copies/mL (depending on assay used). After 12 months, 95 of 124 patients (77%) with lower baseline viral loads and 63 of 76 patients (83%) with high baseline viral loads had on-treatment viral loads below the limit of quantification. Conclusion: Baseline viral load does not affect virologic outcome in HIV-1-infected, antiretroviral-naive participants treated with nevirapine-containing, PI-sparing HAART.

Original languageEnglish (US)
Pages (from-to)317-322
Number of pages6
JournalHIV Clinical Trials
Volume2
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Nevirapine
Highly Active Antiretroviral Therapy
Viral Load
HIV-1
Reverse Transcriptase Inhibitors
Therapeutics
Protease Inhibitors
Nucleosides
Drug Therapy

Keywords

  • HAART
  • Nevirapine
  • Viral load

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. / Raffi, F.; Reliquet, V.; Podzamczer, D.; Pollard, Richard B.

In: HIV Clinical Trials, Vol. 2, No. 4, 2001, p. 317-322.

Research output: Contribution to journalArticle

@article{c752a46c612c4b96b86c72c2d9258bea,
title = "Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads",
abstract = "Purpose: The objective of this analysis was to assess the efficacy of nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing, protease inhibitor (PI)-sparing, three-drug highly active antiretroviral therapy (HAART) in HIV-1-infected, treatment-naive patients with high and low baseline viral loads. Method: A composite analysis was performed of clinical studies including the NNRTI nevirapine that were presented at international conferences between 1998 and October 2000. In all of the studies, nevirapine was administered in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). For a study to be included in the analysis, more than 25{\%} of participants must have had baseline viral loads > 100,000 copies/mL, and more than 25{\%} of participants must have had viral loads < 100,000 copies/mL. Results: After 6 months, 139 of 156 (89{\%}) and 82 of 99 (83{\%}) patients in the low and high baseline viral load groups, respectively, had on-treatment viral loads <200 to 500 copies/mL (depending on assay used). After 12 months, 95 of 124 patients (77{\%}) with lower baseline viral loads and 63 of 76 patients (83{\%}) with high baseline viral loads had on-treatment viral loads below the limit of quantification. Conclusion: Baseline viral load does not affect virologic outcome in HIV-1-infected, antiretroviral-naive participants treated with nevirapine-containing, PI-sparing HAART.",
keywords = "HAART, Nevirapine, Viral load",
author = "F. Raffi and V. Reliquet and D. Podzamczer and Pollard, {Richard B}",
year = "2001",
language = "English (US)",
volume = "2",
pages = "317--322",
journal = "HIV Clinical Trials",
issn = "1528-4336",
publisher = "Thomas Land Publishers Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads

AU - Raffi, F.

AU - Reliquet, V.

AU - Podzamczer, D.

AU - Pollard, Richard B

PY - 2001

Y1 - 2001

N2 - Purpose: The objective of this analysis was to assess the efficacy of nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing, protease inhibitor (PI)-sparing, three-drug highly active antiretroviral therapy (HAART) in HIV-1-infected, treatment-naive patients with high and low baseline viral loads. Method: A composite analysis was performed of clinical studies including the NNRTI nevirapine that were presented at international conferences between 1998 and October 2000. In all of the studies, nevirapine was administered in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). For a study to be included in the analysis, more than 25% of participants must have had baseline viral loads > 100,000 copies/mL, and more than 25% of participants must have had viral loads < 100,000 copies/mL. Results: After 6 months, 139 of 156 (89%) and 82 of 99 (83%) patients in the low and high baseline viral load groups, respectively, had on-treatment viral loads <200 to 500 copies/mL (depending on assay used). After 12 months, 95 of 124 patients (77%) with lower baseline viral loads and 63 of 76 patients (83%) with high baseline viral loads had on-treatment viral loads below the limit of quantification. Conclusion: Baseline viral load does not affect virologic outcome in HIV-1-infected, antiretroviral-naive participants treated with nevirapine-containing, PI-sparing HAART.

AB - Purpose: The objective of this analysis was to assess the efficacy of nonnucleoside reverse transcriptase inhibitor (NNRTI)-containing, protease inhibitor (PI)-sparing, three-drug highly active antiretroviral therapy (HAART) in HIV-1-infected, treatment-naive patients with high and low baseline viral loads. Method: A composite analysis was performed of clinical studies including the NNRTI nevirapine that were presented at international conferences between 1998 and October 2000. In all of the studies, nevirapine was administered in combination with two nucleoside reverse transcriptase inhibitors (NRTIs). For a study to be included in the analysis, more than 25% of participants must have had baseline viral loads > 100,000 copies/mL, and more than 25% of participants must have had viral loads < 100,000 copies/mL. Results: After 6 months, 139 of 156 (89%) and 82 of 99 (83%) patients in the low and high baseline viral load groups, respectively, had on-treatment viral loads <200 to 500 copies/mL (depending on assay used). After 12 months, 95 of 124 patients (77%) with lower baseline viral loads and 63 of 76 patients (83%) with high baseline viral loads had on-treatment viral loads below the limit of quantification. Conclusion: Baseline viral load does not affect virologic outcome in HIV-1-infected, antiretroviral-naive participants treated with nevirapine-containing, PI-sparing HAART.

KW - HAART

KW - Nevirapine

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=0034892588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034892588&partnerID=8YFLogxK

M3 - Article

C2 - 11590534

AN - SCOPUS:0034892588

VL - 2

SP - 317

EP - 322

JO - HIV Clinical Trials

JF - HIV Clinical Trials

SN - 1528-4336

IS - 4

ER -